Assessing Iron Status in CKD Patients: New Laboratory Parameters
نویسندگان
چکیده
Anemia in patients with CKD is due to many factors. Erythropoiesis and iron homeostasis are impaired as a result of a complex chain of events, including the relative deficiency of erythropoietin, chronic inflammation, blood loss, decreased iron absorption and utilization, exogenous iron and erythropoietin acquisition via biologically unregulated mechanisms (blood transfusions and medicinal erythropoietin and iron administration) (Weiss, 2009; Guidi & Santonastaso, 2010; Lankhorst & Wish, 2010).
منابع مشابه
Fibroblast growth factor 23, iron and inflammation – are they related in early stages of chronic kidney disease?
INTRODUCTION Fibroblast growth factor 23 (FGF-23) levels are elevated in impaired renal function. Inflammation and iron are potential regulators of FGF-23. The aim of the study was to evaluate the association between FGF-23 concentration, novel iron status biomarkers and inflammatory parameters among patients with early stages of chronic kidney disease (CKD). MATERIAL AND METHODS The study po...
متن کاملBiomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary
Chronic kidney disease (CKD) is the gradual, progressive deterioration of kidney function, and a condition that affects an estimated 26 million American adults. A common complication of CKD is anemia, which results from inadequate erythropoietin or from iron deficiency as a result of inadequate absorption or mobilization. The management of anemia in CKD patients must strike an appropriate balan...
متن کاملNononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
BACKGROUND Human recombinant erythropoietin (rHuEPO) is widely used to stimulate red blood cell production in patients with anemia due to cancer, renal disease, and other medical conditions, but concern has grown about its overuse and potential for harm. Little is known about the nature of rHuEPO use in hospitalized patients who receive rHuEPO therapy for nononcologic indications. METHODS We ...
متن کاملC.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
BACKGROUND AND OBJECTIVE C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting. METHODS Two hundred seventy two anemic ...
متن کاملبررسی وضعیت ذخایر آهن و شیوع کم خونی فقر آهن در مبتلایان به بیماری مزمن کلیوی در مراحل پیش از دیالیز (pre-dialysis) و همودیالیز نگهدارنده
Background and Objective: Anemia is one of the major disabling consequences in chronic kidney (CKD) disease which has different etiologies .Inadequate production of Erythropoietin (EPO) is the main cause of anemia. Iron shortage is the other important cause. The aim of this study is to evaluate Anemia Prevalence and iron storage in CKD patients in pre-dialysis and hemodialysis stages. Mater...
متن کامل